<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/252044-derivatives-of-piperidinylalkylcarbamates-preparation-method-thereof-and-use-of-same-as-faah-enzyme-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:35:10 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 252044:&quot;DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Derivatives of piperidinyl alkyl carbamates, preparation method thereof on use of same as FAAH enzyme inhibitors The invention relates to a compound having general formula (I), wherein: m - 1 to 4; n represents =1, 2 or 3; o = 1 or 2; A is selected from among one or more X, Y and/or Z groups; X optionally-substituted methylene; Y = C2-alkenylene, optionally substituted; Z = C3-7-cycloalkyl; B = covalent bond or C1-6-alkylene; G = covalent bond, O, S, -CH(OH)-, CO, SO or SO2; R1 represents an aryl- or heteroaryl-type group; R2 = hydrogen or C1-6-alkyl; R3 = hydrogen, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkylene. The inventive compound takes the form of a base, an acid addition salt, a hydrate or a solvate. Said compound is suitable for use as FAAH enzyme inhibitors.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The invention relates to pipendinylalkyl-<br>
carbamate derivatives, to their preparation and to<br>
their application in therapy.<br>
Already known are phenylalkylcarbamate<br>
derivatives, dioxane-2-alkylcarbamate derivatives and<br>
piperidinyl- and piperazinyl-alkylcarbamate<br>
derivatives, described respectively in the documents<br>
WO 2004/067498 A, WO 2004/020430 A and WO 2004/099176,<br><br>
which are inhibitors of the enzyme FAAH (fatty acid<br>
amide hydrolase).<br>
There is still a need to find and to develop<br>
products which inhibit the enzyme FAAH. The compounds<br>
of the invention meet this goal.<br>
The compounds of the invention are of the<br>
general formula (I)<br><br>
in which<br>
m represents an integer from 1 to 4;<br>
n represents an integer 1, 2 or 3;<br>
o an integer 1 or 2;<br>
A is selected from one or more groups X, Y and/or Z;<br><br>
X represents a methylene group optionally<br>
substituted by one or two Ci-6 alkyl, C3-7 cycloalkyl<br>
or C3.7 cycloalkyl-C1-3 alkylene groups;<br>
Y represents either a C2 alkenylene group optionally<br>
substituted by one or two Ci-6 alkyl, C3-7 cycloalkyl<br>
or C3-7 cycloalkyl-C1-3 alkylene groups, or a C2<br>
alkynylene group;<br>
Z represents a group of formula:<br><br>
p represents an integer from 1 to 5;<br>
q and r represent integers and are defined such<br>
that r+q is a number from 1 to 5;<br>
B represents a covalent bond or a Ci-6 alkylene group;<br>
G represents a covalent bond, an oxygen or sulphur<br>
atom or a -CH(OH)-, CO, SO or S02 group;<br>
Ri represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6;<br>
R4 represents a group selected from a furanyl,<br>
pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl,<br>
isothiazolyl, imidazolyl, pyrazolyl, thiadiazolyl,<br>
isothiadiazolyl, oxadiazolyl, thiadiazolyl,<br>
triazolyl, tetrazolyl, phenyl, pyridinyl,<br>
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,<br>
naphthalenyl, quinolinyl, tetrahydroquinolinyl,<br>
isoquinolinyl, tetrahydroisoquinolinyl,<br>
phthalazinyl, quinazolinyl, quinoxalinyl,<br><br>
cinnolinyl, naphthyridinyl, imidazopyrimidinyl,<br>
thienopyrimidinyl, benzofuranyl, dihydrobenzo-<br>
furanyl, benzothienyl, dihydrobenzothienyl,<br>
benzimidazolyl, benzoxazolyl, benzisoxazolyl,<br>
benzothiazolyl, benzisothiazolyl, indolyl,<br>
isoindolyl, indazolyl, pyrrolopyridinyl,<br>
furopyridinyl, dihydrofuropyridinyl,<br>
thienopyridinyl, dihydrothienopyridinyl,<br>
imidazopyridinyl, pyrazolopyridinyl,<br>
oxazolopyridinyl, isoxazolopyridinyl,<br>
thiazolopyridinyl;<br>
R5 represents a halogen atom, a cyano, nitro,<br>
hydroxyl, Cx.6 alkyl, Ci-6 alkoxy, Ci_6 thioalkyl, Ci-6<br>
fluoroalkyl, Ci-6 fluoroalkoxy, Ci-6 fluorothioalkyl,<br>
C3.7 cycloalkyl or C3-7 cycloalkyl-Ci-3 alkylene group<br>
or a group NR7R8, NR7COR8, NR7C02R8, NR7S02R8, COR7/<br>
C02R7; CONR7R8, S02R7, S02NR7R8 or -0- (C1.3 alkylene) -<br>
0-;<br>
R6 represents a phenyl, phenyloxy, benzyloxy,<br>
pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl or<br>
pyrimidinyloxy group; it being possible for the<br>
group or groups R6 to be substituted by one or more<br>
groups R5 identical to or different from one<br>
another;<br>
R7 and R8 represent independently of one another a<br>
hydrogen atom or a d-6 alkyl group, or, with the<br>
atom or atoms which carry them, form a ring<br><br>
selected from an azetidine, pyrrolidine,<br>
piperidine, morpholine, thiomorpholine, azepine or<br>
piperazine ring, this ring being optionally-<br>
substituted by a Ci-s alkyl or benzyl group;<br>
R2 represents a hydrogen atom or a Ci-6 alkyl group;<br>
R3 represents a hydrogen atom or a Ci-6 alkyl, C3.7<br>
cycloalkyl or C3.7 cycloalkyl-Ci-3 alkylene group.<br>
In the context of the invention the compounds<br>
of general formula (I) may therefore comprise two or<br>
more groups A identical to or different from one<br>
another.<br>
Among the compounds of general formula (I) a<br>
first subgroup of compounds is composed of the<br>
compounds for which:<br>
m represents an integer from 1 to 4;<br>
n represents an integer 1 or 2;<br>
o an integer 1 or 2;<br>
A is selected from one or more groups X and/or Y;<br>
X represents a methylene group optionally<br>
substituted by one or two Ci-6 alkyl groups, more<br>
particularly methyl;<br>
Y represents a C2 alkynylene group;<br>
B represents a covalent bond or a Ci-6 alkylene group,<br>
more particularly a methylene or an ethylene;<br>
G represents a covalent bond or an oxygen atom;<br>
Ri represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6, more particularly by<br><br>
one or two groups R5 and/or R6;<br>
R4 represents a group selected from an oxazolyl,<br>
isoxazolyl, thiazolyl, phenyl, pyridinyl,<br>
naphthalenyl, quinolinyl, isoquinolinyl;<br>
R5 represents a halogen atom, more particularly a<br>
chlorine, a bromine or a fluorine, a cyano group, a<br>
group NR7R8, or a Ci-6 alkyl group, more particularly<br>
a methyl or an isopropyl, a Ci-6 alkoxy group, more<br>
particularly a methoxy or an ethoxy, a Ci-6 fluoro-<br>
alkyl group, more particularly a trifluoromethyl,<br>
or a Ci-6 fluoroalkoxy group, more particularly a<br>
trifluoromethoxy;<br>
R6 represents a phenyl, phenyloxy or pyrimidinyloxy<br>
group; it being possible for the group or groups R6<br>
to be substituted by one or more groups R5 identical<br>
to or different from one another;<br>
R7 and R8 represent independently of one another a<br>
Ci-6 alkyl group, more particularly a methyl;<br>
R2 represents a hydrogen atom or a Ci-6 alkyl group;<br>
R3 represents a hydrogen atom or a Cx.6 alkyl, C3.7<br>
cycloalkyl or C3.7 cycloalkyl-Ci-3 alkylene group.<br>
Among the compounds of general formula (I)<br>
and of the first subgroup, a second subgroup of<br>
compounds is composed of the compounds for which:<br>
n, o, A, B, G, Ri, R2 and R3 are as defined in the<br>
formula (I) or in the subgroup above;<br>
m represents an integer 1 or 2, more particularly 1.<br><br>
Among the compounds of general formula (I)<br>
and of the subgroups above, a third subgroup of<br>
compounds is composed of the compounds for which:<br>
m, A, B, G, Ri, R2 and R3 are as defined in the formula<br>
(I) or in the subgroups above;<br>
n is 2;<br>
o is 2.<br>
Among the compounds of general formula (I)<br>
and of the subgroups above, a fourth subgroup of<br>
compounds is composed of the compounds for which:<br>
m, n, o, A, B, G, R2 and R3 are as defined in the<br>
formula (I) or in the subgroups above;<br>
Rx represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6/ more particularly by one or<br>
two groups R5 and/or R6;<br>
R4 represents a group selected from an oxazolyl,<br>
isoxazolyl, phenyl or naphthalenyl;<br>
R5 represents a halogen atom, more particularly a<br>
chlorine, a bromine or a fluorine, a cyano group, a<br>
group NR7R8, a Ci-6 alkyl group, more particularly a<br>
methyl or an isopropyl, a Cx.6 alkoxy group, more<br>
particularly a methoxy or an ethoxy, a Ci-6 fluoro-<br>
alkyl group, more particularly a trifluoromethyl,<br>
or a Ci-6 fluoroalkoxy group, more particularly a<br>
trifluoromethoxy;<br>
R6 represents a phenyl, phenyloxy or pyrimidinyloxy<br>
group; it being possible for the group or groups R6<br><br>
to be substituted by one or more groups R5 identical<br>
to or different from one another;<br>
R7 and RQ represent independently of one another a<br>
Ci-6 alkyl group, more particularly a methyl.<br>
Among the compounds of general formula (I) a<br>
fifth subgroup of compounds is composed of the<br>
compounds for which:<br>
m, n, o, A, B, G, and Ri are as defined in the formula<br>
(I) or in the subgroups above;<br>
R2 represents a hydrogen atom;<br>
R3 represents a hydrogen atom or a Ci-6 alkyl group, more<br>
particularly a methyl.<br>
Among the compounds of general formula (I)<br>
mention may be made of the following compounds:<br>
-	2-(methylamino)-2-oxoethyl {l-[(3,4'-difluorobi-<br>
phenyl-4-yl)methyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[(3-chloro-4'-fluorobi-<br>
phenyl-4-yl)methyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[3-(4-fluorophenoxy)-<br>
benzyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[4-(4-chloro-3-fluoro-<br>
phenoxy) benzyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[3-(trifluoro-<br>
methoxy)benzyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[4-(trifluoro-<br>
methoxy)benzyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-tert-butoxy-<br><br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-tert-butoxy-<br>
benzyDpiperidin^-yljmethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(2,4-dichloro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(2,5-dichloro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3,5-dichloro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(2-chloro-5-fluoro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-chloro-2-fluoro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-chloro-5-methyl-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[(3,4'-difluorobi-<br>
phenyl-4-yl)methyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[(3-chloro-4'-fluoro-<br>
biphenyl-4-yl)methyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[4-(4-chloro-3-<br>
fluorophenoxy)benzyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[3-(4-fluorophenoxy)-<br>
benzyl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[3-(trifluoromethoxy)-<br>
benzyl]piperidin-4-yljmethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[4-(trifluoromethoxy)-<br>
benzyl]piperidin-4-yl}methylcarbamate;<br><br>
-	2-(methylamino)-2-oxoethyl {l-[3-(pyrimidin-2-yloxy)-<br>
benzyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(2-chloro-4-fluoro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-chloro-4-fluoro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(3-cyano-5-fluoro-<br>
benzyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[3-(4-fluorophenoxy)-<br>
benzyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{ [3-(4-chlorophenyl)-<br>
isoxazol-5-yl]methyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{[5-(4-chlorophenyl)-<br>
1,3-oxazol-2-yl]methyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-({4- [4-(trifluoro-<br>
methyl)phenyl]-1,3-thiazol-2-yl}methyl)piperidin-4-yl]-<br>
methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(l-{[3-(4-chlorophenyl)-<br>
isoxazol-5-yl]methyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(1-{[5-(4-chlorophenyl)-<br>
1,3-oxazol-2-yl]methyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-({4-[4-(trifluoro-<br>
methyl)phenyl]-1,3 -thiazol-2-yl}methyl)piperidin-4-yl]-<br>
ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[5-(4-chlorophenyl)-<br>
isoxazol-3-yl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(l-{2-[3-(4-chloro-<br><br>
phenyl)isoxazol-5-yl]ethyl}piperidin-4-yl)ethyl-<br>
carbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[3-(4-chlorophenyl)-<br>
isoxazol-5-yl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{3-[3-(4-chlorophenyl)-<br>
isoxazol-5-yl]propyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{3-[5-(4-chlorophenyl)-<br>
isoxazol-3-yl]propyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[1-(2-chloro-4-fluoro-<br>
phenyl)ethyl]piperidin-4-yl}methylcarbamat e;<br>
-	2-(methylamino)-2-oxoethyl (l-{l-[3-(4-chloro-<br>
phenoxy)phenyl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{l-[2-chloro-3-(4-<br>
chlorophenoxy)phenyl]ethyl}piperidin-4-yl)methyl-<br>
carbamate ;<br>
-	2-(methylamino)-2-oxoethyl 2-(1-{l-[3-(trifluoro-<br>
methoxy)phenyl]ethyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[1-(2-chloro-4-<br>
fluorophenyl)ethyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[4-(4-chlorophenyl)but-<br>
3-yn-1-yl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[5-(4-chlorophenyl)-<br>
pent-4-yn-1-yl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[5-(2,5-dichloro-<br>
phenyl)pent-4-yn-1-yl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[4-(4-chlorophenyl)but-<br>
3-yn-1-yl]piperidin-4-yl}methylcarbamate;<br><br>
-	2-(methylamino)-2-oxoethyl {l-[4-(4-chloro-2-fluoro-<br>
phenyl)but-3-yn-1-yl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[4-(2,5-dichloro-<br>
phenyl)but-3-yn-l-yl]piperidin-4-yl}methylcarbamate.<br>
Among the compounds of general formula (I) a<br>
subclass of compounds is composed of the compounds of<br>
the general formula (I'):<br><br>
in which<br>
m represents an integer from 1 to 4;<br>
n represents an integer 1, 2 or 3;<br>
o an integer 1 or 2;<br>
A is selected from one or more groups X, Y and/or Z;<br>
X represents a methylene group optionally<br>
substituted by one or two Ci-6 alkyl, C3.7 cycloalkyl<br>
or C3-7 cycloalkyl-C1-3 alkylene groups;<br>
Y represents either a C2 alkenylene group optionally<br>
substituted by one or two Ci-g alkyl, C3.7 cycloalkyl<br>
or C3.7 cycloalkyl-C1-3 alkylene groups, or a C2<br>
alkynylene group;<br>
Z represents a group of formula:<br><br><br>
p represents an integer from 1 to 5;<br>
q and r represent integers and are defined such<br>
that r+q is a number from 1 to 5;<br>
B represents a covalent bond or a (Vs alkylene group;<br>
G represents a covalent bond, an oxygen or sulphur<br>
atom or a -CH(OH)-, CO, SO or S02 group;<br>
Ri represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6;<br>
R4 represents a group selected from a furanyl,<br>
pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl,<br>
isothiazolyl, imidazolyl, pyrazolyl, thiadiazolyl,<br>
isothiadiazolyl, oxadiazolyl, thiadiazolyl,<br>
triazolyl, tetrazolyl, phenyl, pyridinyl,<br>
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,<br>
naphthalenyl, quinolinyl, tetrahydroquinolinyl,<br>
isoquinolinyl, tetrahydroisoquinolinyl,<br>
phthalazinyl, quinazolinyl, quinoxalinyl,<br>
cinnolinyl, naphthyridinyl, imidazopyrimidinyl,<br>
thienopyrimidinyl, benzofuranyl, dihydrobenzo-<br>
furanyl, benzothienyl, dihydrobenzothienyl,<br>
benzimidazolyl, benzoxazolyl, benzisoxazolyl,<br>
benzothiazolyl, benzisothiazolyl, indolyl,<br>
isoindolyl, indazolyl, pyrrolopyridinyl,<br>
furopyridinyl, dihydrofuropyridinyl,<br>
thienopyridinyl, dihydrothienopyridinyl,<br>
imidazopyridinyl, pyrazolopyridinyl,<br>
oxazolopyridinyl, isoxazolopyridinyl,<br><br>
thiazolopyridinyl;<br>
R5 represents a halogen atom, a cyano, nitro,<br>
hydroxyl, Ci-6 alkyl, Ci_6 alkoxy, Ci-6 thioalkyl, Cx.6<br>
fluoroalkyl, Ci_6 f luoroalkoxy, Ci-6 fluorothioalkyl,<br>
C3-7 cycloalkyl or C3-7 cycloalkyl-Ci-3 alkylene group<br>
or a group NR7R8, NR7COR8, NR7C02R8, NR7S02R8, C0R7,<br>
C02R7, CONR7R8, S02R7, S02NR7R8 or -0-(C1-3 alkylene)-<br>
0-;<br>
R6 represents a phenyl, phenyloxy, benzyloxy,<br>
pyridinyl, pyrazinyl, pyridazinyl or pyrimidinyl<br>
group; it being possible for the group or groups R6<br>
to be substituted by one or more groups R5 identical<br>
to or different from one another;<br>
R7 and R8 represent independently of one another a<br>
hydrogen atom or a Ci_6 alkyl group, or, with the<br>
atom or atoms which carry them, form a ring<br>
selected from an azetidine, pyrrolidine,<br>
piperidine, morpholine, thiomorpholine, azepine or<br>
piperazine ring, this ring being optionally<br>
substituted by a Ci_6 alkyl or benzyl group;<br>
R2 represents a hydrogen atom or a Ci-6 alkyl group;<br>
R3 represents a hydrogen atom or a Ci-6 alkyl, C3.7<br>
cycloalkyl or C3.7 cycloalkyl-Ci-3 alkylene group.<br>
Among the compounds of general formula (I') a<br>
first subgroup of compounds is composed of the<br>
compounds for which:<br>
m represents an integer from 1 to 3;<br><br>
n represents an integer 1 or 2;<br>
o an integer 2;<br>
A is a methylene group;<br>
B represents a covalent bond or a Ci-6 alkylene group,<br>
more particularly a methylene or an ethylene;<br>
G represents a covalent bond or an oxygen atom;<br>
Ri represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6/ more particularly by<br>
one or two groups R5 and/or R6;<br>
R4 represents a group selected from a phenyl,<br>
pyridinyl, naphthalenyl, isoquinolinyl;<br>
R5 represents a halogen atom, more particularly a<br>
chlorine, a bromine or a fluorine, a cyano group,<br>
an iV/itf-dimethylamino group, a Ci-6 alkyl group, more<br>
particularly an isopropyl, a Ci-6 alkoxy group, more<br>
particularly a methoxy or an ethoxy, or a Ci-6<br>
fluoroalkyl group, more particularly a trifluoro-<br>
methyl;<br>
R6 represents a phenyl group;<br>
R2 represents a hydrogen atom or a Ci-6 alkyl group;<br>
R3 represents a hydrogen atom or a Ci-6 alkyl, C3-7<br>
cycloalkyl or C3.7 cycloalkyl-Ci_3 alkylene group.<br>
Among the compounds of general formula (I') a<br>
second subgroup of compounds is composed of the<br>
compounds for which:<br>
m, n, o, A, B, G and Ri are as defined in subgroup 1;<br>
R2 represents hydrogen atom;<br><br>
R3 represents a hydrogen atom or a Ci-6 alkyl group, more<br>
particularly a methyl.<br>
Among the compounds of general formula (I')<br>
mention may be made of the following compounds:<br>
-	2-(methylamino)-2-oxoethyl {l-[(2-chlorophenyl)-<br>
methyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[(4-chlorophenyl)-<br>
methyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[(4-chlorophenyl)-<br>
methyl]piperidin-4-yl}carbamate,•<br>
-	2-(methylamino)-2-oxoethyl (1-[4-(1-methylethyl)-<br>
phenyl]methyl piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(biphenyl-4-ylmethyl)-<br>
piperidin-4-yl]carbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(biphenyl-4-ylmethyl)-<br>
piperidin-4-yl]methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(biphenyl-4-yl-<br>
methyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(2-biphenyl-4-ylethyl)-<br>
piperidin-4-yl]carbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(naphthalen-2-yl-<br>
methyl)piperidin-4-yl]methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[(4-bromophenyl)-<br>
methyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(1-{[3-(trifluoro-<br>
methyl)phenyl]methyl}piperidin-4-yl)ethylcarbamate;<br>
-	2 -(methyl amino)-2-oxoethyl 2-(l-{[4-(trifluoro-<br><br>
methyl)phenyl]methyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[(2,3-dichloro-<br>
phenyl)methyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[(3,4-dichloro-<br>
phenyl)methyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(naphthalen-l-yl-<br>
methyl )piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(naphthalen-2-yl-<br>
methyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-[1-(pyridin-2-yl-<br>
methyl)piperidin-4-yl]ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[4-fluoro-2-<br>
(methyloxy)phenyl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[(4-fluorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)carbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[(4-chlorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)carbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[(2,4-dichloro-<br>
phenyDoxy] ethyl}piperidin-4-yl) carbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[(4-chlorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl l-{2-[(2,4-dichloro-<br>
phenyl)oxy]ethyl} piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(l-{2-[(4-fluorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(1-{2-[(4-chlorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)ethylcarbamate;<br><br>
-	2-(methylamino)-2-oxoethyl (l-{2-[ (4-fluorophenyl)-<br>
oxy]ethyl} pyrrolidin-3-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[(4-chlorophenyl)-<br>
oxy]ethyl}pyrrolidin-3-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[3-(trifluoro-<br>
methyl)phenyl]ethyl}piperidin-4-yl)carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[2-(4-chlorophenyl)-<br>
ethyl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[2-(4-cyanophenyl)-<br>
ethyl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[(isoquinolin-5-<br>
yl)oxy]ethyl}piperidin-4-yl)carbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(2-naphthalen-l-yl-<br>
ethyl)piperidin-4-yl]carbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(2-naphthalen-2-yl-<br>
ethyl)piperidin-4-yl]carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[3-(4-chlorophenyl)-<br>
propyl]piperidin-4-yl}carbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{3-[4-(methyloxy)-<br>
phenyl]propyl}piperidin-4-yl)carbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[2-(3-chlorophenyl)-<br>
ethyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{2-[4-(ethyloxy)-<br>
phenyl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (l-{2-[4-(dimethylamino)-<br>
phenyl]ethyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl {l-[2-(2,4-dichloro-<br><br>
phenyl)ethyl]piperidin-4-yl}methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-(2-naphthalen-l-yl-<br>
ethyl)piperidin-4-yl]methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl [1-U-naphthalen^-yl-<br>
ethyDpiperidin^-y^methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl (1-{3-[4-(methyloxy)-<br>
phenyl]propyl}piperidin-4-yl)methylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[2-(2-chlorophenyl)-<br>
ethyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[2-(4-fluorophenyl)-<br>
ethyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(l-{2-[4-(ethyloxy)-<br>
phenyl]ethyl}piperidin-4-yl)ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-{l-[2-(2-chloro-6-<br>
fluorophenyl)ethyl]piperidin-4-yl}ethylcarbamate;<br>
-	2-(methylamino)-2-oxoethyl 2-(1-{3-[4-(methyloxy)-<br>
phenyl]propyl}piperidin-4-yl)ethylcarbamate.<br>
The compounds of general formula (I) may<br>
include one or more asymmetric carbons. They may exist<br>
in the form of enantiomers or diastereoisomers. These<br>
enantiomers and diastereoisomers, and also mixtures<br>
thereof, including the racemic mixtures, form part of<br>
the invention.<br>
The compounds of formula (I) may exist in the<br>
form of bases or of addition salts with acids. Such<br>
addition salts form part of the invention.<br>
These salts are advantageously prepared with<br><br>
pharmaceutically acceptable acids, although the salts<br>
of other acids which are of use, for example, for<br>
purifying or isolating compounds of formula (I)<br>
likewise form part of the invention.<br>
The compounds of general formula (I) may be<br>
in the form of hydrates or solvates, namely in the form<br>
of associations or combinations with one or more<br>
molecules of water or with a solvent. Such hydrates and<br>
solvates likewise form part of the invention.<br>
In the context of the invention the terms are<br>
understood as follows:<br>
Ct-z/ where t and z may take the values from 1 to 7,<br>
is a carbon chain which may have from t to z carbon<br>
atoms; for example, Ci-3 is a carbon chain which may<br>
have from 1 to 3 carbon atoms;<br>
alkyl is a saturated, linear or branched aliphatic<br>
group; for example, a Ci-6 alkyl group represents a<br>
linear or branched carbon chain of 1 to 6 carbon<br>
atoms, more particularly a methyl, ethyl, propyl,<br>
isopropyl, butyl, isobutyl, tert-butyl, pentyl or<br>
hexyl;<br>
alkylene is a saturated, linear or branched<br>
divalent alkyl group; for example, a Ci-3 alkylene<br>
group represents a linear or branched, divalent<br>
carbon chain of 1 to 3 carbon atoms, more<br>
particularly a methylene, ethylene, 1-methyl-<br>
ethylene or propylene;<br><br>
cycloalkyl is a cyclic alkyl group; for example, a<br>
C3-7 cycloalkyl group represents a cyclic carbon<br>
group of 3 to 7 carbon atoms, more particularly a<br>
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or<br>
cycloheptyl;<br>
alkenylene is a divalent unsaturated aliphatic<br>
group having 2 carbons, more particularly an<br>
ethylene;<br>
C2 alkynylene is a -CsC- group;<br>
alkoxy is an -O-alkyl group having a saturated,<br>
linear or branched aliphatic chain;<br>
thioalkyl is an -S-alkyl group having a saturated,<br>
linear or branched aliphatic chain;<br>
fluoroalkyl is an alkyl group of which one or more<br>
hydrogen atoms have been substituted by a fluorine<br>
atom;<br>
fluoroalkoxy is an alkoxy group of which one or<br>
more hydrogen atoms have been substituted by a<br>
fluorine atom;<br>
fluorothioalkyl is a thioalkyl group of which one<br>
or more hydrogen atoms have been substituted by a<br>
fluorine atom; and<br>
halogen atom is a fluorine, a chlorine, a bromine<br>
or an iodine.<br>
In the text below, a protective group Pg is<br>
understood to be a group which makes it possible on the<br>
one hand for a reactive function such as a hydroxyl or<br><br>
an amine to be protected during a synthesis and on the<br>
other hand for the reactive function to be regenerated<br>
intact at the end of synthesis. Examples of protective<br>
groups and also of methods of protection and<br>
deprotection are given in "Protective Groups in Organic<br>
Synthesis", Green et al., 2nd Edition (John Wiley &amp;<br>
Sons, Inc., New York).<br>
The compounds of the invention may be<br>
prepared according to various methods, which are<br>
illustrated by scheme 1 below.<br>
Thus a first method (scheme 1) involves<br>
reacting a compound of general formula (II), in which<br>
B, R2, n and o are as defined in the general formula<br>
(I), with a derivative of general formula (III), in<br>
which W represents a mesylate or tosylate group or a<br>
chlorine, bromine or iodine atom and m, G, A and Ri are<br>
as defined in the general formula (I), in the presence<br>
of a base such as triethylamine, sodium hydride, sodium<br>
tert-butoxide or sodium carbonate in a solvent such as<br>
tetrahydrofuran, acetonitrile, dimethyl sulphoxide or<br>
dimethylformamide at a temperature between 0°C and the<br>
reflux temperature of the solvent.<br><br><br>
The oxazolidine-dione of general formula<br>
(Ila) thus obtained is subsequently converted into a<br>
compound of general formula (I), by aminolysis using an<br>
amine of general formula R3NH2 in which R3 is as defined<br>
in the general formula (I). The aminolysis reaction may<br>
be carried out in a solvent such as methanol, ethanol<br>
or a solvent mixture such as methanol and<br>
tetrahydrofuran or methanol and dioxane.<br>
A variant form of obtaining compounds of<br>
general formula (I) (scheme 1) involves converting a<br>
compound of general formula (II) as defined above by<br><br>
aminolysis, under the conditions described above, using<br>
an amine of general formula R3NH2 as defined above, to<br>
give a carbamate-amide derivative of general formula<br>
(la) in which B, R2, R3, n and o are as defined in the<br>
general formula (I). The compound of general formula<br>
(I) is then obtained by reacting the compound (la) with<br>
a derivative of general formula (III) as defined above,<br>
under the conditions described above.<br>
The carbamate-amide derivative of general<br>
formula (la) as defined above may also be obtained from<br>
the carbamate-ester of general formula (lb), in which<br>
B, R2, n and o are as defined in the general formula<br>
(I), PG represents a protective group such as a Boc<br>
(tert-butyloxycarbonyl) and R represents a methyl or<br>
ethyl group, by aminolysis using an amine of general<br>
formula R3NH2 as defined above and under the conditions<br>
described above, then by deprotection, in the presence<br>
for example of a solution of hydrochloric acid (5N) in<br>
isopropanol.<br>
The carbamate-esters (lb) may be prepared<br>
according to the method illustrated by scheme 2 below.<br><br><br>
According to scheme 2 the carbamate-ester of<br>
general formula (lb) is obtained by reacting an amine<br>
of general formula (IV), in which B, n and o are as<br>
defined in the general formula (I) and PG represents a<br>
protective group such as a Boc, with a carbonate of<br>
general formula (V), in which V represents a hydrogen<br>
atom or a nitro group, R2 is as defined in the general<br>
formula (I) and R represents a methyl or ethyl group.<br>
When the method of preparing them is not<br>
described the compounds of general formula (II) may be<br>
prepared according to methods which are described in<br>
the literature or according to methods similar to those<br>
described or known to the skilled person.<br>
The carbonates of general formula (V) may be<br>
prepared according to any method described in the<br>
literature, by reaction for example of an alcohol of<br>
general formula HOCHR2COOR where R represents a methyl<br>
or ethyl group with phenyl chloroformate or 4-nitro-<br>
phenyl chloroformate in the presence of a base such as<br>
triethylamine or diisopropylethylamine.<br>
The compounds of general formulae (III) and<br>
(IV) and the amines of general formula R3NH2 are<br>
available commercially or are prepared according to<br>
methods which are described in the literature or which<br>
are known to the skilled person.<br>
The compounds of general formula (la) in<br>
which B, R2, R3, n and o are as defined in the general<br><br>
formula (I) are novel and likewise form part of the<br>
invention. They are useful as synthesis intermediates<br>
for the preparation of compounds of general formula<br>
(I).<br>
The compounds of general formula (Ila) in<br>
which m, G, A, Ri, B, R2, n and o are as defined in the<br>
general formula (I), with the exception of the compound<br>
3-[1-(phenylmethyl)-4-piperidinyl]-2,4-oxazolidine-<br>
dione, are novel and likewise form part of the<br>
invention. They are useful as synthesis intermediates<br>
for preparing compounds of general formula (I).<br>
The examples which now follow illustrate the<br>
preparation of some compounds of the invention. These<br>
examples are not limitative and serve merely to<br>
illustrate the invention. The microanalyses, the IR and<br>
NMR spectra and/or the LC-MS (liquid chromatography<br>
coupled to mass spectroscopy) confirm the structures<br>
and the purities of the compounds obtained.<br>
M.P. (°C) represents the melting point in<br>
degrees Celsius.<br>
The numbers indicated between brackets in the<br>
titles of the examples correspond to those in the 1st<br>
column of the subsequent table.<br>
Example 1 (compound 25)<br>
2-(methylamino)-2-oxoethyl 2-[1-(biphenyl-4-ylmethyl)-<br>
piperidin-4-yl]ethylcarbamate<br><br><br>
1.1.	3-(2-piperidin-4-ylethyl)-1,3-oxa-<br>
zolidine-2;4-dione hydrochloride<br>
A solution of 10 g (77.40 mmol) of<br>
2-piperidin-4-ylethanol, 22.33 g (85.14 mmol) of<br>
triphenylphosphine and 9.3 9 g (92.88 mmol) of 1,3-oxa-<br>
zolidine-2,4-dione (J. Med. Chem. 1991, 34, 1538-44) in<br>
150 ml of tetrahydrofuran, cooled to approximately<br>
-10°C, is admixed dropwise under an inert atmosphere<br>
with a solution of 15.65 g (77.40 mmol) of diisopropyl<br>
azodicarboxylate (DIAD) in 25 ml of tetrahydrofuran,<br>
during which the temperature of the reaction mixture is<br>
held between -10°C and 0°C. Stirring is continued at<br>
0°C for 1 hour and then at 25°C for 22 hours. The solid<br>
formed is collected by filtration, washed repeatedly<br>
with tetrahydrofuran and then dried under vacuum at<br>
approximately 70°C. This solid is then taken up in a<br>
solution of hydrochloric acid (5N) in isopropanol. The<br>
solid formed is collected by filtration and then washed<br>
with ethyl acetate and ether.<br>
Drying under vacuum at approximately 70°C<br>
gives 6.45 g of hydrochloride in the form of a white<br>
solid.<br>
M.P. (°C): 178°C<br>
1.2.	3-{2-[l-(biphenyl-4-ylmethyl)piperidin-<br>
4-yl]ethyl}-l,3-oxazolidine-2,4-dione<br><br>
A solution of 0.40 g (1.61 mmol) of<br>
3-(2-piperidin-4-ylethyl)-1,3-oxazolidine-2,4-dione<br>
hydrochloride, prepared in step 1.1., 0.326 g<br>
(1.61 mmol) of 4-(chloromethyl)biphenyl and 0.51 g<br>
(4.82 mmol) of sodium carbonate in 3 ml of acetonitrile<br>
is heated at reflux for 17 hours. It is left to return<br>
to ambient temperature and filtered and the filtrate is<br>
concentrated under reduced pressure. The residue is<br>
taken up in dichloromethane and water and the aqueous<br>
phase is separated off and extracted twice with<br>
dichloromethane. The combined organic phases are washed<br>
with saturated aqueous sodium chloride solution and<br>
dried over sodium sulphate. Following evaporation of<br>
the solvent, the residue obtained is purified by<br>
chromatography on silica gel, eluting with a 97/3 then<br>
95/5 mixture of dichloromethane and methanol.<br>
This gives 0.46 g of product in the form of a<br>
beige solid.<br>
1.3. 2-(methylamino)-2-oxoethyl 2-[l-(bi-<br>
phenyl-4-ylmethyl)piperidin-4-yl]ethylcarbamate<br>
A solution of 0.45 g (1.19 mmol) of<br>
3-{2-[1-(biphenyl-4-ylmethyl)piperidin-4-yl]ethyl}-l,3-<br>
oxazolidine-2,4-dione, obtained in step 1.2., in 5 ml<br>
of methanol is admixed with 3 ml (5.97 mmol) of a<br>
solution of methylamine (2M) in tetrahydrofuran.<br>
Stirring is continued at ambient temperature for 17<br>
hours. Following concentration under reduced pressure,<br><br>
the residue obtained is purified by chromatography on<br>
silica gel, eluting with a 95/5 then 90/10 mixture of<br>
dichloromethane and methanol. A yellow paste is<br>
obtained which is crystallized from diisopropyl ether.<br>
This gives 0.40 g of product in the form of a<br>
yellow solid.<br>
LC-MS: M+H = 410<br>
M.P. (°C): 106-110°C<br>
XH NMR (CDC13) 5 (ppm) : 1.2-1.50 (unresolved complex,<br>
5H); 1.70 (m, 2H); 2.0 (broad t, 2H); 2.90 (d, 3H); 3.0<br>
(m, 2H); 3.30 (q, 2H); 3.55 (s, 2H); 4.60 (s, 2H); 4.80<br>
(broad s, 1H) ; 6.15 (broad s, 1H) ; 7.40 (m, 5H) ; 7.60<br>
(m, 4H).<br>
Example 2 (compound 52)<br>
2-(methylamino)-2-oxoethyl l-{2-[4-fluoro-2-(methoxy)-<br>
phenyl]ethyl}piperidin-4-yl)methylcarbamate<br><br>
2.1. 1,1-dimethylethyl 4-<br>
{[(methylsulphonyl)oxy]methyl}piperidine-l-carboxylate<br>
A solution of 10.08 g (46.81 mmol) of<br>
1,1-dimethylethyl 4-(hydroxymethyl)piperidine-l-<br>
carboxylate and 9.90 ml (70.21 mmol) of triethylamine<br>
in 100 ml of dichloromethane, cooled to approximately<br><br>
0°C, is admixed dropwise under an inert atmosphere with<br>
a solution of 4 ml (51.49 mmol) of mesyl chloride in<br>
10 ml of dichloromethane. The bath is removed and<br>
stirring is continued at ambient temperature for 30<br>
minutes. Water is added to the reaction mixture, the<br>
aqueous phase is separated off and extracted once with<br>
dichloromethane, the combined organic phases are wasHed<br>
with water and dried over sodium sulphate and the<br>
filtrate is concentrated under reduced pressure.<br>
This gives 13.7 g of product in the form of<br>
an orange-coloured oil, which is used as it is in the<br>
following step.<br>
2.2. 1,1-dimethylethyl 4-[ (2,4-dioxo-l,3-<br>
oxazolidin-3-yl)methyl]piperidine-1-carboxylate<br>
A suspension of 13.60 g (46.36 mmol) of<br>
1,1-dimethylethyl 4-{[(methylsulphonyl)oxy]methyl}-<br>
piperidine-1-carboxylate, prepared in step 2.1., 9.37 g<br>
(92.72 mmol) of 1,3-oxazolidine-2,4-dione and 16.02 g<br>
(139.08 mmol) of 1,1,3,3-tetramethylguanidine in a<br>
mixture of 180 ml of tetrahydrofuran and 3 0 ml of<br>
dimethylformamide is heated at reflux for 24 hours. It<br>
is allowed to return to ambient temperature and is<br>
concentrated under reduced pressure. The residue is<br>
taken up in dichloromethane and water and the aqueous<br>
phase is separated off and extracted twice with<br>
dichloromethane. The combined organic phases are washed<br>
with saturated aqueous sodium chloride solution and<br><br>
dried over sodium sulphate. Following evaporation of<br>
the solvent, the residue obtained is purified by-<br>
chroma tography on silica gel, eluting with a 98/2 then<br>
95/5 mixture of dichloromethane and methanol.<br>
This gives 12.53 g of product in the form of<br>
an orange-brown solid.<br>
2.3.	3-(piperidin-4-ylmethyl) -1, 3 -<br>
oxazolidine-2,4-dione hydrochloride<br>
A suspension of 12.51 g (41.95 mmol) of<br>
1,1-dimethylethyl 4-[(2,4-dioxo-l,3-oxazolidin-3-yl)-<br>
methyl]piperidine-l-carboxylate, obtained in step 2.2.,<br>
in 65 ml of dioxane is admixed with 38.10 ml<br>
(209.75 mmol) of a solution of hydrochloric acid (5N)<br>
in isopropanol. Stirring is continued at approximately<br>
60°C for 17 hours. The suspension is allowed to return<br>
to ambient temperature. The solid formed is collected<br>
by filtration and then washed repeatedly with ether and<br>
dried under vacuum at approximately 70°C.<br>
This gives 8.41 g of product in the form of a<br>
white solid.<br>
M.P. (°C): 195-200°C<br>
2.4.	3- [ (l-{2- [4-fluoro-2-(methoxy)phenyl]-<br>
ethyl}piperidin-4-yl)methyl]-1,3-oxazolidine-2,4-dione<br>
The method described in Example 1 (step 1.2.)<br>
is used. Starting from 0.4 0 g (1.70 mmol) of<br>
3-(piperidin-4-ylmethyl)-1,3-oxazolidine-2,4-dione<br>
hydrochloride, prepared in step 2.3., 0.423 g<br><br>
(1.70 mmol) of 2-[4-fluoro-2-(methyloxy)phenyl]ethyl<br>
methanesulphonate [EP1340761] and 0.54 g (5.11 mmol) of<br>
sodium carbonate gives, after treatment, 0.590 g of<br>
product in the form of a viscous yellow oil, which is<br>
used as it is in the following step.<br>
2.5. 2-(methylamino)-2-oxoethyl l-{2-[4-<br>
fluoro-2 -(methoxy)phenyl]ethyl]piperidin-4-yl)methyl-<br>
carbamate<br>
The procedure described in Example 1 (step<br>
1.3.) is followed. Starting from 0.58 g (1.66 mmol) of<br>
3-[(l-{2-[4-fluoro-2-(methoxy)phenyl]ethyl}piperidin-4-<br>
yl)methyl]-1,3-oxazolidine-2,4-dione, prepared in step<br>
2.4., and 8.28 ml (16.55 mmol) of a solution of methyl-<br>
amine (2M) in tetrahydrofuran, and after chromatography<br>
on silica gel, eluting with a 95/5/0.5 mixture of<br>
dichloromethane, methanol and 28% ammonia, followed by<br>
washing with diisopropyl ether, gives 0.315 g of<br>
product in the form of a white solid.<br>
LC-MS: M+H =3 82<br>
M.P. (°C): 126-128°C<br>
XH NMR (DMSO) 6 (ppm) : 1.10 (m, 2H); 1.35 (broad s, 1H) ;<br>
1.60 (broad d, 2H); 1.85 (broad t, 2H); 2.40 (m, 2H);<br>
2.60 (m, 5H); 2.90 (m, 4H); 3.80 (s, 3H); 4.30 (s, 2H) ;<br>
6.65 (td, 1H); 6.80 (dd, 1H); 7.15 (m, 2H); 7.70 (broad<br>
s, 1H).	I<br><br>
Example 3 (compound 68)<br>
2-(methylamino)-2-oxoethyl l-{2-[(2,4-dichlorophenyl)-<br>
oxy]ethyl}piperidin-4-yl)carbamate<br><br>
3.1.	1,1-dimethylethyl 4-[({[2-(ethyloxy)-2-<br>
oxoethyl]oxyjcarbonyl)amino]piperidine-1-carboxylate<br>
A suspension of 5.09 g (25.42 mmol) of<br>
1,1-dimethylethyl 4-aminopiperidine-l-carboxylate and<br>
13.45 g (59.99 mmol) of ethyl [(phenyloxycarbonyl)oxy]-<br>
acetate (J. Med. Chem., 1999, 42, 277-90) in 300 ml of<br>
toluene is heated at reflux for 30 hours.<br>
The suspension is allowed to return to<br>
ambient temperature, the insoluble material is<br>
separated off by filtration and the filtrate is<br>
concentrated under reduced pressure. The residue thus<br>
obtained is purified by chromatography on silica gel,<br>
eluting with a 3 0/70 mixture of ethyl acetate and<br>
cyclohexane.<br>
This gives 6.62 g of product in the form of a<br>
light-coloured yellow oil.<br>
3.2.	1,1-dimethylethyl 4-[({[2-(methyl-<br>
amino)-2-oxoethyl]oxy}carbonyl)amino]piperidine-1-<br>
carboxylate<br>
The procedure of Example 1 (step 1.3.) is<br><br>
repeated. Starting from 6.33 g (19.16 mmol) of 1,1-di-<br>
methylethyl 4-[({[2-(ethyloxy)-2-oxoethyl]oxy}-<br>
carbonyl)amino]piperidine-1-carboxylate, prepared in<br>
step 3.1., and 47.90 ml (95.81 mmol) of a solution of<br>
methylamine (2M) in tetrahydrofuran gives 5.90 g of<br>
product in the form of a sticky yellow paste.<br>
3.3.	2-(methylamino)-2-oxoethyl piperidin-4-<br>
ylcarbamate hydrochloride<br>
The method described in Example 2 (step 2.3.)<br>
is used. Starting from 5.90 g (18.71 mmol) of<br>
1,1-dimethylethyl 4-[({[2-methylamino)-2-oxoethyl]oxy}-<br>
carbonyl)amino]piperidine-1-carboxylate, prepared in<br>
step 3.2., and 17 ml (93.53 mmol) of a solution of<br>
hydrochloric acid (5N) in isopropanol gives 3.83 g of<br>
hydrochloride in the form of a white solid after<br>
washing with diisopropyl ether and drying under vacuum<br>
at approximately 70°C.<br>
M.P. (°C): 153°C<br>
3.4.	2-(methylamino)-2-oxoethyl l-{2-[2,4-<br>
dichlorophenyl)oxy]ethyl}piperidin-4-yl)carbamate<br>
The method described in Example 1 (step 1.2.)<br>
is used. Starting from 0.51 g (1.89 mmol) of 2-(methyl-<br>
amino) -2-oxoethyl piperidin-4-ylcarbamate hydro-<br>
chloride, prepared in step 3.3., 0.50 g (1.99 mmol) of<br>
1-[(2-bromoethyl)oxy]-2,4-dichlorobenzene and 0.60 g<br>
(5.68 mmol) of sodium carbonate, and after<br>
chromatography on silica gel, eluting with a 94/6/0.6<br><br>
then 95/5/0.5 mixture of dichloromethane, methanol and<br>
28% ammonia, followed by washing with diisopropyl<br>
ether, gives 0.44 g of product in the form of a white<br>
solid.<br>
LC-MS: M+H =404<br>
M.P. (°C): 115-119°C<br>
AH NMR (CDC13) 5 (ppm) : 1.50 (m, 2H) ; 2.0 (broad d, 2H) ;<br>
2.35 (broad t, 2H); 2.90 (d, 3H); 3.0 (m, 4H); 3.60 (m,<br>
1H); 4.15 (t, 2H); 4.60 (s, 2H); 4.75 (broad d, 1H);<br>
6.15 (broads, 1H); 6.85 (d, 1H); 7.20 (dd, 1H); 7.40<br>
(d, 1H) .<br>
Example 4 (compound 4)<br>
2-(methylamino)-2-oxoethyl {l-[(4-chlorophenyl)methyl] -<br>
piperidin-4-yl}methylcarbamate hydrochloride<br><br>
4.1. 2-(methylamino)-2-oxoethyl (piperidin-<br>
4-yl)methylcarbamate hydrochloride<br>
A solution of 0.50 g (2.13 mmol) of<br>
3-piperidin-4-ylmethyl)-1,3-oxozolidine-2,4-dione<br>
hydrochloride, obtained in step 2.3., and 5.3 0 ml<br>
(10.65 mmol) of a solution of methylamine (2M) in<br>
tetrahydrofuran in 10 ml of methanol is stirred at<br>
ambient temperature for 15 hours. Following<br>
concentration under reduced pressure, the residue<br>
obtained is treated with a solution of hydrochloric<br><br>
acid (5N) in isopropanol. The hydrochloride obtained is<br>
collected by filtration, washed with diisopropyl ether<br>
and dried under vacuum at approximately 70°C. This<br>
gives 0.49 g of a white powder.<br>
4.2. 2-(methylamino)-2-oxoethyl {l-[(4-<br>
chlorophenyl)methyl]piperidin-4-yl}methylcarbamate<br>
hydrochloride<br>
A mixture of 0.118 g (0.44 mmol) of<br>
2-(methylamino)-2-oxoethyl (piperidin-4-<br>
yl)methylcarbamate hydrochloride, 0.283 g (1.33 mmol)<br>
of sodium triacetoxyborohydride and 0.626 g (4.45 mmol)<br>
of 4-chlorobenzaldehyde in 5 ml of a 1% solution of<br>
acetic acid in N,N'-dimethylformamide is stirred at<br>
ambient temperature. After 24 hours of stirring, 2 g of<br>
DOWEX 50WX2 acidic resin (Fluka) are added and stirring<br>
is continued at ambient temperature for one hour. The<br>
mixture is filtered and the resin is rinsed with 3<br>
times 5 ml of N,N'-dimethylformamide, 3 times 5 ml of<br>
dichloromethane and 3 times 5 ml of methanol. The resin<br>
is subsequently treated for an hour at ambient<br>
temperature with 8 ml of a solution (2M) of ammonia in<br>
methanol. The mixture is filtered and the filtrate is<br>
concentrated under vacuum. The product is purified by<br>
chromatography on silica gel, eluting with a 94/6<br>
mixture of dichloromethane and methanol containing 2%<br>
of 28% aqueous ammonia solution. The oily residue<br>
obtained is treated with 5 ml of a solution of<br><br>
hydrochloric acid (0.1N) in isopropanol. Concentration<br>
gives 0.067 g of a white powder.<br>
M.P. (8C): 220-222°C<br>
LC-MS: M+H = 354<br>
XH NMR (DMSO-dg / D20): 8 (ppm): 1.20 (m, 2H); 1.40 (m,<br>
1H); 1.60 (m, 2H); 1.90 (t, 2H); 2.70 (s, 3H); 2.75 (d,<br>
2H); 2.90 (d, 2H); 3.40 (s, 2H); 4.30 (s, 2H); 7.95 (m,<br>
4H) .<br>
Table 1 below illustrates the chemical<br>
structures and the physical properties of some<br>
compounds according to the invention.<br>
In this table:<br>
-	in the "base or salt" column, "base" signifies that<br>
the compound is in the form of the free base, whereas<br>
"HCl" represents a compound in hydrochloride form, and<br>
the ratio between brackets is the (acid:base) ratio,<br>
-	t-BuO, Me, Et and i-Pr represent, respectively, tert-<br>
butoxy, methyl, ethyl and isopropyl groups, and<br>
-	Ph represents a phenyl group.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
The compounds of the invention were subjected<br>
to pharmacological tests allowing determination of<br>
their inhibitory effect on the enzyme FAAH (fatty acid<br>
amide hydrolase).<br>
The inhibitory activity was demonstrated in a<br>
radioenzymatic assay based on measuring the product of<br>
hydrolysis ( [1-3H] ethanolamine) of anandamide [1-3H<br>
ethanol amine] by FAAH (Life Sciences (1995), 56, 1999-<br>
2005 and Journal of Pharmacology and Experimental<br>
Therapeutics (1997), 283, 729-734). Accordingly, mouse<br>
brains (minus the cerebellum) are removed and stored at<br>
-80°C. Membrane homogenates are prepared at the time of<br>
use by homogenizing the tissues in a Polytron in a<br>
10 mM Tris-HCl buffer (pH 8.0) containing 150 mM NaCl<br>
and 1 mM EDTA. The enzymatic reaction is subsequently<br>
conducted in 70 /xl of buffer containing bovine serum<br><br>
albumin without fatty acids (l mg/ml). In succession<br>
the test compounds, at various concentrations,<br>
anandamide [1-3H ethanolamine] (specific activity:<br>
15-20 Ci/mmol) diluted to 10 /xM with cold anandamide,<br>
and the membrane preparation (400 //g of frozen tissue<br>
per assay) are added. After 15 minutes at 25°C, the<br>
enzymatic reaction is terminated by adding 140 /xl of<br>
chloroform/methanol (2:1). The mixture is stirred for<br>
10 minutes and then centrifuged for 15 minutes at<br>
3500 g. An aliquot (30 (il) of the aqueous phase<br>
containing the ethanolamine [1-3H] is counted by liquid<br>
scintillation.<br>
Under these conditions the most active<br>
compounds of the invention exhibit IC50 values<br>
(concentration inhibiting by 50% the control enzymatic<br>
activity of FAAH) of between 0.001 and 1 /iM.<br>
Table 2 below presents the IC50 values of some<br>
compounds according to the invention.<br><br>
It is therefore apparent that the compounds<br>
according to the invention have an inhibitory activity<br>
on the FAAH enzyme.<br>
The in vivo activity of the compounds of the<br><br>
Accordingly, intraperitoneal (i.p.)<br>
administration of PBQ (phenylbenzoquinone, 2 mg/kg in a<br>
0.9% sodium chloride solution containing 5% of ethanol)<br>
to male OF1 mice weighing 2 5 to 30 g causes abdominal<br>
stretches, on average 30 twists or contractions during<br>
the period from 5 to 15 minutes after injection. The<br>
test compounds are administered orally (p.o.) or<br>
intraperitoneally (i.p.) in suspension in Tween 80 at<br>
0.5%, 60 minutes or 120 minutes before the<br>
administration of PBQ. Under these conditions the most<br>
potent compounds of the invention reduce by 35% to 70%<br>
the number of stretches induced by PBQ, within a dose<br>
range of between 1 and 3 0 mg/kg.<br>
For example, compound 26 of the table reduces<br>
by 56% the number of stretches induced by PBQ, at a<br>
dose of 10 mg/kg p.o. at 12 0 minutes.<br>
The enzyme FAAH (Chemistry and Physics of<br>
Lipids, (2000), 108, 107-121) catalyses the hydrolysis<br>
of endogenous derivatives of amides and of esters of<br>
various fatty acids such as N-arachidonoylethanolamine<br>
(anandamide), W-palmitoylethanolamine, .N-oleoyl-<br>
ethanolamine, oleamide or 2-arachidonoylglycerol. These<br>
derivatives exert various pharmacological activities by<br>
interacting, inter alia, with cannabinoid and vanilloid<br>
receptors.<br>
The compounds of the invention block this<br>
degradation pathway and increase the tissue level of<br><br>
these endogenous substances. They can be used in this<br>
respect in the prevention and treatment of pathologies<br>
in which endogenous cannabinoids and/or any other<br>
substrates metabolized by the FAAH enzyme are involved.<br>
Mention may be made, for example, of the<br>
following diseases and conditions:<br>
pain, especially acute or chronic pain of neurogenic<br>
type: migraine, neuropathic pain, including forms<br>
associated with the herpes virus and with diabetes;<br>
acute or chronic pain associated with inflammatory<br>
diseases: arthritis, rheumatoid arthritis, osteo-<br>
arthritis, spondylitis, gout, vasculitis, Crohn's<br>
disease, irritable bowel syndrome;<br>
acute or chronic peripheral pain;<br>
dizziness, vomiting, nausea, especially those<br>
subsequent to chemotherapy;<br>
eating disorders, especially anorexia and cachexia of<br>
various kinds;<br>
neurological and psychiatric pathologies: shaking,<br>
dyskinesia, dystonia, spasticity, obsessive-compulsive<br>
behaviours, Tourette's syndrome, all forms of<br>
depression and anxiety of any kind and cause, mood<br>
disorders, psychoses;<br>
acute and chronic neurodegenerative diseases:<br>
Parkinson's disease, Alzheimer's disease, senile<br>
dementia, Huntington's chorea, lesions associated with<br>
cerebral ischemia and with cranial and medullary<br><br>
trauma;<br>
epilepsy;<br>
sleep disorders, including sleep apnoea;<br>
cardiovascular diseases, especially hypertension,<br>
cardiac arrhythmias, arteriosclerosis, heart attack,<br>
cardiac ischemias;<br>
renal ischemia;<br>
cancej?«T benign skin tumours, papillomas and brain<br>
tumours, prostate tumours, brain tumours (glio-<br>
blastomas, medulloepitheliomas, medulloblastomas,<br>
neuroblastomas, tumours of embryonic origin, astro-<br>
cytomas, astroblastomas, ependyomas, oligodendro-<br>
gliomas, plexus tumour, neuroepitheliomas, epiphysial<br>
tumour, ependymoblastomas, malignant meningiomas,<br>
sarcomatoses, malignant melanomas, schwannomas);<br>
disorders of the immune system7™especially autoimmune<br>
diseases: psoriasis, lupus erythematosis, diseases of<br>
the connective tissue or collagen diseases, Sjogren's<br>
syndrome, ankylosing spondylarthritis, undifferentiated<br>
spondylarthritis, Behcet's disease, haemolytic auto-<br>
immune anaemias, multiple sclerosis, amyotrophic<br>
lateral sclerosis, amyloses, transplant rejection,<br>
diseases affecting the plasmocytic line;<br>
allergic diseases: immediate or delayed hyper-<br>
sensitivity, allergic rhinitis or conjunctivitis,<br>
contact dermatitis;<br>
parasitic, viral or bacterial infectious diseases:<br><br>
AIDS, meningitis; inflammatory diseases, especially<br>
diseases of the joints: arthritis, rheumatoid<br>
arthritis, osteoarthritis, spondylitis, gout,<br>
vasculitis, Crohn's disease, irritable bowel syndrome;<br>
osteoporosis; ocular conditions: ocular hypertension,<br>
glaucoma;<br>
pulmonary conditions: diseases of the respiratory<br>
tract, bronchospasms, coughing, asthma, chronic<br>
bronchitis, chronic obstruction of the respiratory<br>
tract, emphysema;<br>
gastrointestinal diseases: irritable bowel syndrome,<br>
intestinal inflammatory disorders, ulcers, diarrhoea;<br>
urinary incontinence and bladder inflammation.<br>
The use of a compound of formula (I) in base,<br>
salt, hydrate or pharmaceutically acceptable solvate<br>
form for preparing a medicinal product intended for<br>
treating the abovementioned pathologies forms an<br>
integral part of the invention.<br>
The invention likewise provides medicinal<br>
products which comprise a compound of formula (I), or a<br>
salt or else a hydrate or a pharmaceutically acceptable<br>
solvate of the compound of formula (I). These medicinal<br>
products are employed in therapy, particularly in the<br>
treatment of the abovementioned pathologies.<br>
According to another of its aspects the<br>
present invention provides pharmaceutical compositions<br>
comprising as active principle at least one compound<br><br>
according to the invention. These pharmaceutical<br>
compositions include an effective dose of a compound<br>
according to the invention, or a salt or a hydrate or a<br>
pharmaceutically acceptable solvate of the said<br>
compound, and, optionally, one or more pharmaceutically<br>
acceptable excipients.<br>
The said excipients are selected, according<br>
to the pharmaceutical form and the desired mode of<br>
administration, from the customary excipients, which<br>
are known to the skilled person.<br>
In the pharmaceutical compositions of the<br>
present invention for oral, sublingual, subcutaneous,<br>
intramuscular, intravenous, topical, local, intra-<br>
thecal, intranasal, transdermal, pulmonary, ocular or<br>
rectal administration, the active principle of formula<br>
(I) above, or its salt, solvate or hydrate where<br>
appropriate, may be administered in a single-dose<br>
administration form, in a mixture with conventional<br>
pharmaceutical excipients, to animals and to humans for<br>
the prophylaxis or treatment of the above disorders or<br>
diseases.<br>
The unit-dose administration forms which are<br>
appropriate include oral forms such as tablets, soft or<br>
hard gelatine capsules, powders, granules, chewing gums<br>
and oral solutions or suspensions, forms for<br>
sublingual, buccal, intratracheal, intraocular and<br>
intranasal administration, and for administration by<br><br>
inhalation, forms for subcutaneous, intramuscular or<br>
intravenous administration and forms for rectal or<br>
vaginal administration. For topical application the<br>
compounds according to the invention may be used in<br>
creams, ointments or lotions.<br>
By way of example a single-dose<br>
administration form of a compound according to the<br>
invention in tablet form may comprise the following<br>
components:<br>
Compound according to the invention 50.0 mg<br>
Mannitol	223.75 mg<br>
Croscaramellose sodium	6.0 mg<br>
Maize starch	15.0 mg<br>
Hydroxypropyl-methylcellulose	2.25 mg<br>
Magnesium stearate	3.0 mg<br>
The said single-dose forms contain a dose<br>
permitting daily administration of 0.01 to 2 0 mg of<br>
active principle per kg of body weight, depending on<br>
the pharmaceutical form.<br>
There may be particular cases in which higher<br>
or lower dosages are appropriate; such dosages also<br>
belong to the invention. In accordance with customary<br>
practice, the dosage appropriate to each patient is<br>
determined by the doctor according to the mode of<br>
administration, the weight and the response of the said<br>
patient.<br>
According to another of its aspects the<br><br>
invention also provides a method of treating the<br>
pathologies indicated above, which comprises<br>
administering an effective dose of a compound according<br>
to the invention, one of its pharmaceutically<br>
acceptable salts, a solvate or a hydrate of the said<br>
compound.<br><br>
We claim:<br>
1. Compound of the formula (I)<br><br>
in which<br>
m represents an integer from 1 to 4;<br>
n represents an integer 1, 2 or 3;<br>
o an integer 1 or 2;<br>
A is selected from one or more groups X, Y and/or Z;<br>
X represents a methylene group optionally<br>
substituted by one or two C1-6 alkyl, C3-7 cycloalkyl<br>
or C3-7 cycloalkyl-C1-3 alkylene groups;<br>
Y represents either a C2 alkenylene group optionally<br>
substituted by one or two C1-6 alkyl, C3-7 cycloalkyl<br>
or C3-7 cycloalkyl-C1-3 alkylene groups, or a C2<br>
alkynylene group;<br>
Z represents a group of formula:<br><br>
p represents an integer from 1 to 5;<br>
q and r represent integers and are defined such<br>
that r+q is a number from 1 to 5;<br>
B represents a covalent bond or a C1-6 alkylene group;<br><br>
G represents a covalent bond, an oxygen or sulphur atom<br>
or a -CH(OH)-, CO, SO or SO2 group;<br>
R1 represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6;<br>
R4 represents a group selected from a furanyl,<br>
pyrrolyl, thienyl, oxazolyl, isoxazolyl, thiazolyl,<br>
isothiazolyl, imidazolyl, pyrazolyl, thiadiazolyl,<br>
isothiadiazolyl, oxadiazolyl, thiadiazolyl,<br>
triazolyl, tetrazolyl, phenyl, pyridinyl,<br>
pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl,<br>
naphthalenyl, quinolinyl, tetrahydroquinolinyl,<br>
isoquinolinyl, tetrahydroisoquinolinyl, phthalazinyl,<br>
quinazolinyl, quinoxalinyl, cinnolinyl,<br>
naphthyridinyl, imidazopyrimidinyl,<br>
thienopyrimidinyl, benzofuranyl, dihydrobenzofuranyl,<br>
benzothienyl, dihydrobenzothienyl, benzimidazolyl,<br>
benzoxazolyl, benzisoxazolyl, benzothiazolyl,<br>
benzisothiazolyl, indolyl, isoindolyl, indazolyl,<br>
pyrrolopyridinyl, furopyridinyl,<br>
dihydrofuropyridinyl, thienopyridinyl,<br>
dihydrothienopyridinyl, imidazopyridinyl,<br>
pyrazolopyridinyl, oxazolopyridinyl,<br>
isoxazolopyridinyl, thiazolopyridinyl;<br>
R5 represents a halogen atom, a cyano, nitro,<br>
hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 thioalkyl, C1-6<br>
fluoroalkyl, C1-6 fluoroalkoxy, C1-6 fluorothioalkyl, C3-<br>
7 cycloalkyl or C3-7 cycloalkyl-C1-3 alkylene group or a<br>
group NR7R8, NR7CORB, NR7CO2R8, NR7SO2R8, COR7,<br><br>
CO2R7, CONR7R8, SO2R7, SO2NR7R8 or -O-(C1-3 alkylene)-O-;<br>
R6 represents a phenyl, phenyloxy, benzyloxy,<br>
pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl or<br>
pyrimidinyloxy group; it being possible for the group<br>
or groups R6 to be substituted by one or more groups<br>
R5 identical to or different from one another;<br>
R7 and R8 represent independently of one another a<br>
hydrogen atom or a C1-6 alkyl group, or, with the atom<br>
or atoms which carry them, form a ring selected from<br>
an azetidine, pyrrolidine, piperidine, morpholine,<br>
thiomorpholine, azepine or piperazine ring, this ring<br>
being optionally substituted by a C1-6 alkyl or benzyl<br>
group;<br>
R2 represents a hydrogen atom or a C1_6 alkyl group;<br>
R3 represents a hydrogen atom or a C1-6 alkyl, C3-7<br>
cycloalkyl or C3-7 cycloalkyl-C1-3 alkylene group;<br>
in the form of a base, addition salt with an acid,<br>
hydrate or solvate.<br>
2. Compound of formula (I) as claimed in claim 1,<br>
wherein<br>
m represents an integer from 1 to 4;<br>
n represents an integer 1 or 2;<br>
o an integer 1 or 2;<br>
A is selected from one or more groups X and/or Y;<br>
X represents a methylene group optionally substituted<br>
by one or two C1-6 alkyl groups;<br>
Y represents a C2 alkynylene group;<br><br>
B represents a covalent bond or a C1-6 alkylene group;<br>
G represents a covalent bond or an oxygen atom;<br>
R1 represents a group R4 optionally substituted by one<br>
or more groups R5 and/or R6;<br>
R4 represents a group selected from an oxazolyl,<br>
isoxazolyl, thiazolyl, phenyl, pyridinyl,<br>
naphthalenyl, quinolinyl, isoquinolinyl;<br>
R5 represents a halogen atom, a cyano group, a group<br>
NR7R8, or a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6<br>
fluoroalkyl group or a C1-6 fluoroalkoxy group;<br>
R6 represents a phenyl, phenyloxy or pyrimidinyloxy<br>
group; it being possible for the group or groups R6<br>
to be substituted by one or more groups R5 identical<br>
to or different from one another;<br>
R7 and R8 represent independently of one another a C1-6<br>
alkyl group;<br>
R2 represents a hydrogen atom or a C1-6 alkyl group;<br>
R3 represents a hydrogen atom or a C1-6 alkyl, C3-7<br>
cycloalkyl or C3-7 cycloalkyl-C1-3 alkylene group;<br>
in the form of a base, addition salt with an acid,<br>
hydrate or solvate.<br>
3.	Compound of formula (I) as claimed in claim 1 or 2,<br>
wherein:<br>
m represents an integer 1 or 2;<br>
in the form of a base, addition salt with an acid,<br>
hydrate or solvate.<br>
4.	Compound of formula (I) as claimed in any one of<br><br>
claims 1 to 3, wherein:<br>
n is 2;<br>
o is 2;<br>
in the form of a base, addition salt with an acid,<br>
hydrate or solvate.<br>
5.	Compound of formula (I) as claimed in any one of<br>
Claims 1 to 4, wherein:<br>
R1 represents a group R4 optionally substituted by one or<br>
more groups R5 and/or Re;<br>
R4 represents a group selected from an oxazolyl,<br>
isoxazolyl, phenyl or naphthalenyl;<br>
R5 represents a halogen atom, a cyano group, a group<br>
NR7R8, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6<br>
fluoroalkyl group, or a C1-6 fluoroalkoxy group;<br>
R6 represents a phenyl, phenyloxy or pyrimidinyloxy<br>
group; it being possible for the group or groups R6<br>
to be substituted by one or more groups R5 identical<br>
to or different from one another;<br>
R7 and R8 represent independently of one another a C1-6<br>
alkyl group;<br>
in the form of a base, addition salt with an acid,<br>
hydrate or solvate.<br>
6.	Compound of formula (I) as claimed in any one of<br>
Claims 1 to 5, wherein:<br>
R2 represents a hydrogen atom;<br>
R3 represents a hydrogen atom or a C1-6 alkyl group;<br>
in the form of a base, addition salt with an acid,<br><br>
hydrate or solvate.<br>
7.	Process for preparing a compound of formula (I) as<br>
claimed in any one of claims 1 to 6, comprising the step<br>
consisting in converting the oxazolidine-dione of general<br>
formula (II))<br><br>
in which A, B, G, R1, R2, m, n and o are as defined in<br>
the formula (I) as claimed in Claim 1 by aminolysis<br>
using an amine of general formula R3NH2 in which R3 is as<br>
defined in the formula (I) as claimed in claim 1.<br>
8.	Process for preparing a compound of formula (I) as<br>
claimed in any one of claims 1 to 6, comprising the step<br>
consisting in converting the carbamate-amide derivative<br>
of general formula (Ia)<br><br>
in which B, R2, R3, n and o are as defined in the formula<br>
(I) as claimed in claim 1,<br>
by reaction with a derivative of general formula (III)<br>
R1—G-[A]m-w (III)<br>
in which W represents a mesylate or tosylate group or a<br>
chlorine, bromine or iodine atom and m, G, A and R1 are<br><br>
as defined in the formula (I) as claimed in Claim 1.<br>
9.	Compound of the general formula (IIa)<br><br>
in which A, B, G, R1, R2, m, n and o are as defined in<br>
the formula (I) as claimed in claim 1,<br>
with the exception of 3-[1-(phenylmethyl)-4-piperidinyl]-<br>
2, 4-oxazolidinedione.<br>
10.	Compound of the general formula (Ia)<br><br>
in which B, R2, R3, n and o are as defined in the formula<br>
(I) as claimed in claim 1.<br>
11.	Pharmaceutical composition comprising at least one<br>
compound of formula (I) as claimed in any one of Claims<br>
1 to 6, in base, salt, hydrate or pharmaceutically<br>
acceptable solvate form, and, optionally, one or more<br>
pharmaceutically acceptable excipients.<br>
12.	Compound of formula (I) as claimed in any one of<br>
Claims 1 to 6, in base, salt, hydrate or pharmaceutically<br><br>
acceptable solvate form, for its use as a medicinal<br>
product.<br>
13.	A pharmaceutical composition comprising a compound of<br>
formula (I) as claimed in any one of Claims 1 to 6, in<br>
base, salt, hydrate or pharmaceutically acceptable<br>
solvate form, which is useful for preventing or treating<br>
a pathology in which endogenous cannabinoids and/or any<br>
other substances metabolized by the enzyme FAAH are<br>
involved.<br>
14.	A pharmaceutical composition comprising a compound of<br>
formula (I) as claimed in any one of Claims 1 to 6, in<br>
base, salt, hydrate or pharmaceutically acceptable<br>
solvate form, which is useful for preventing or treating<br>
acute or chronic pain, dizziness, vomiting, nausea,<br>
eating disorders, neurological and psychiatric<br>
pathologies, acute or chronic neurodegenerative diseases,<br>
epilepsy, sleep disorders, cardiovascular diseases, renal<br>
ischemia, cancers, disorders of the immune system,<br>
allergic diseases, parasitic, viral or bacterial<br>
infectious diseases, inflammatory diseases, osteoporosis,<br>
ocular conditions, pulmonary conditions, gastrointestinal<br>
diseases or urinary incontinence.<br><br><br>
Derivatives of piperidinyl alkyl carbamates, preparation method thereof on use of same as<br>
FAAH enzyme inhibitors<br><br>
The invention relates to a compound having general formula (I), wherein:<br>
m - 1 to 4; n represents =1, 2 or 3; o = 1 or 2; A is selected from among one or more X, Y<br>
and/or Z groups; X optionally-substituted methylene; Y = C2-alkenylene, optionally<br>
substituted; Z = C3-7-cycloalkyl; B = covalent bond or C1-6-alkylene; G = covalent bond, O, S,<br>
-CH(OH)-, CO, SO or SO2; R1 represents an aryl- or heteroaryl-type group; R2 = hydrogen or<br>
C1-6-alkyl; R3 = hydrogen, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkylene.<br>
The inventive compound takes the form of a base, an acid addition salt, a hydrate or a solvate.<br>
Said compound is suitable for use as FAAH enzyme inhibitors.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1hc2lnbm1lbnQucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-asignment.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1kZXNjcmlwdGlvbihjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1mb3JtLTMucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1mb3JtLTUucGRm" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDIzMzIta29sbnAtMjAwNi1pbnRlcm5hdGlvbmFsIHNlYXJjaCBhdXRob3JpdHkgcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">02332-kolnp-2006-international search authority report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWFic3RyYWN0IDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-abstract 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUFCU1RSQUNULnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUFNQU5ERUQgQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-AMANDED CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUFTU0lHTk1FTlQgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-ASSIGNMENT 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUFTU0lHTk1FTlQtMS4yLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-ASSIGNMENT-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFIDEuMi5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-CORRESPONDENCE 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWNvcnJlc3BvbmRlbmNlIDEuMy5wZGY=" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-correspondence 1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFLTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-CORRESPONDENCE-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFLTEuNC5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-CORRESPONDENCE-1.4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUNPUlJFU1BPTkRFTkNFLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkgMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-description (complete) 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LURFU0NSSVBUSU9OIChDT01QTEVURSkucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWZvcm0gMS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-form 1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMTMtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 13-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMTMucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMTgtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 18-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LWZvcm0gMi0xLjEucGRm" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-form 2-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMi5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 3-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUZPUk0gNS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-FORM 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdQQS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GPA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtQUJTVFJBQ1QucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtQ0xBSU1TLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtREVTQ1JJUFRJT04gKENPTVBMRVRFKS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtRk9STSAxLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-FORM 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtRk9STSAyLnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-FORM 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LUdSQU5URUQtU1BFQ0lGSUNBVElPTi5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-GRANTED-SPECIFICATION.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1rb2xucC0yMDA2LW90aGVycyAxLjIucGRm" target="_blank" style="word-wrap:break-word;">2332-kolnp-2006-others 1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LU9USEVSUy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-OTHERS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LU9USEVSUy0xLjIucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-OTHERS-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LU9USEVSUy5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LVBFVElUSU9OIFVOREVSIFJVTEUgMTM3LnBkZg==" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LVBFVElUSU9OIFVOREVSIFJVTFIgMTM3IDEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-PETITION UNDER RULR 137 1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC0xLjEucGRm" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-REPLY TO EXAMINATION REPORT-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVC5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-REPLY TO EXAMINATION REPORT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjMzMi1LT0xOUC0yMDA2LVRSQU5TTEFURUQgQ09QWSBPRiBQUklPUklUWSBET0NVTUVOVC5wZGY=" target="_blank" style="word-wrap:break-word;">2332-KOLNP-2006-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDIzMzIta29sbnAtMjAwNi5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-02332-kolnp-2006.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="252043-acylaminothiazole-derivatives-and-use-thereof-as-beta-amyloid-inhibitors.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="252045-reinforced-soil-structure-and-method-for-building-it.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>252044</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>2332/KOLNP/2006</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>17/2012</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>27-Apr-2012</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>23-Apr-2012</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>17-Aug-2006</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SANOFI AVENTIS</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>174, AVENUE DE FRANCE F-75013, PARIS</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>ABOUABDELLAH, AHMED</td>
											<td>2 RUE DES EGLANTIERS, FR-94320, THIAIS</td>
										</tr>
										<tr>
											<td>2</td>
											<td>HOORNAERT CHRISTIAN</td>
											<td>49 AVENUE ARISTIDE BRIAND FE-92160, ANTONY</td>
										</tr>
										<tr>
											<td>3</td>
											<td>JEUNESSE JEAN</td>
											<td>6 RUE ANDRE MESSAGER, ER-75018, PARIS</td>
										</tr>
										<tr>
											<td>4</td>
											<td>ALMARIO GARCIA ANTONIO</td>
											<td>26, AVENUE ROGER SALENGRO, FR-92290, CHATENAY MALABRY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/4468</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/FR2005/000452</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-02-25</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>04/01,952</td>
									<td>2004-02-26</td>
								    <td>France</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/252044-derivatives-of-piperidinylalkylcarbamates-preparation-method-thereof-and-use-of-same-as-faah-enzyme-inhibitors by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 13:35:11 GMT -->
</html>
